Inhibikase raises $50M from RA Capital to fund Phase 3 PAH trial

Inhibikase Therapeutics (Nasdaq: IKT) raised $50 million in gross proceeds by selling 25,000,000 shares of common stock directly to RA Capital Management through its at-the-market (ATM) facility.

Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases. Its lead candidate, IKT-001, is a prodrug of imatinib mesylate being repurposed for pulmonary arterial hypertension (PAH), a progressive condition affecting around 50,000 Americans.

The company expects the new capital, plus existing cash, to fund operations through the topline data readout in Part B of its global Phase 3 IMPROVE-PAH study — provided outstanding Series A and B warrants are fully exercised.

The offering was made under a Form S-3 shelf registration effective since June 27, 2025, with a prospectus supplement filed December 19, 2025. An ATM facility lets public companies raise capital incrementally, often with greater pricing flexibility.

Selling a large block of shares could dilute existing shareholders. The company also flags execution risk on its Phase 3 strategy and the outcome of the trial itself.

Direct participation from RA Capital Management, a healthcare-focused institutional investor, reads as a vote of confidence and could lend support to the share price as Inhibikase pushes toward its pivotal readout.